Last updated
Amgen: M&A Activity
Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
Source: Endpoints News
- What happened
- Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
- Who
- Amgen · Biotech & Pharma · USA
- When
- 2026-08-19
- Source
- Endpoints News
- So what
- Consolidation shifts the leadership question from growth to integration.
The leadership read
Consolidation shifts the leadership question from growth to integration. For Amgen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: Against a Talent Market Index of 122.7 (Hot) (up 17.8 month-on-month), Americas is at rising (+34.4pts) on signal share.
Amgen: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 32 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 4 tracked across 79 days.
MitchelLake in this thematic
Also at Amgen →
More signals across Biotech & Pharma
M&A Activity · Americas
BioMarin Pharmaceutical Inc. →BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.
M&A Activity · Americas
Biogen →Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
M&A Activity · Americas
Teva Pharmaceuticals →Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
M&A Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
M&A Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
M&A Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search: Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record